DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TYSABRI (natalizumab)
       *****************************************************
       #Post#: 51--------------------------------------------------
       Smokers run increased risk of developing anti-natalizumab antibo
       dies
       By: agate Date: December 7, 2013, 9:36 am
       ---------------------------------------------------------
       From Multiple Sclerosis Journal, December 5, 2013:
       [quote]Smokers run increased risk of developing anti-natalizumab
       antibodies
       AK Hedström1
       L Alfredsson1
       M Lundkvist Ryner2
       A Fogdell-Hahn2
       Jan Hillert2
       T Olsson3
       1Institute of Environmental Medicine, Karolinska Institutet,
       Sweden
       2Multiple Sclerosis Research Group, Department of Clinical
       Neuroscience and Center for Molecular Medicine, Karolinska
       Institutet at Karolinska University Hospital, Sweden
       3Neuroimmunology Unit, Department of Clinical Neuroscience and
       Center for Molecular Medicine, Karolinska Institutet at
       Karolinska University Hospital, Sweden
       Anna Karin Hedström, Institute of Environmental Medicine,
       Karolinska Institutet, Stockholm, 14153, Sweden. Email:
       anna.hedstrom@ki.se
       Background:
       Smoking may contribute to the induction of neutralizing
       antibodies to interferon β-1a.
       Objective:
       In this study, we aimed to investigate the influence of smoking
       on the risk of developing antibodies to natalizumab, another
       biological drug in the treatment of multiple sclerosis.
       Methods: This report is based on 1338 natalizumab-treated
       multiple sclerosis patients included in either of two Swedish
       case-control studies in which information on smoking habits was
       collected. Using logistic regression, patients with different
       smoking habits were compared regarding risk of developing
       anti-natalizumab antibodies, by calculating odds ratios with 95%
       confidence intervals.
       Results:
       Compared with nonsmokers, the odds ratio of developing
       anti-natalizumab antibodies was 2.4 (95% CI 1.2–4.4) for
       patients who smoked at the time of screening, and a significant
       trend showed higher risk of developing antibodies with higher
       intensity of smoking. When smoking within two years prior to
       screening was considered, the odds ratio of developing
       anti-natalizumab antibodies was 2.7 (1.5–5.1).
       Interpretations:
       The finding strengthens our hypothesis of the lungs as
       immune-reactive organs on irritation in relation to autoimmune
       responses, and may also be of clinical relevance since
       antibodies against natalizumab abrogate the therapeutic effect
       of the treatment.[/quote]
       This abstract can be seen here
  HTML http://msj.sagepub.com/content/early/2013/12/05/1352458513515086.abstract?papetoc.
       *****************************************************